Cited 251 times in
Targeted gene silencing using RGD-labeled chitosan nanoparticles
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 남은지 | - |
dc.date.accessioned | 2015-04-23T17:08:46Z | - |
dc.date.available | 2015-04-23T17:08:46Z | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 1078-0432 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/101908 | - |
dc.description.abstract | PURPOSE: This study aimed to develop an Arg-Gly-Asp (RGD) peptide-labeled chitosan nanoparticle (RGD-CH-NP) as a novel tumor targeted delivery system for short interfering RNA (siRNA). EXPERIMENTAL DESIGN: RGD peptide conjugated with chitosan by thiolation reaction was confirmed by proton-NMR (H-NMR). Binding of RGD-CH-NP with alphanubeta3 integrin was examined by flow cytometry and fluorescence microscopy. Antitumor efficacy was examined in orthotopic mouse models of ovarian carcinoma. RESULTS: We show that RGD-CH-NP loaded with siRNA significantly increased selective intratumoral delivery in orthotopic animal models of ovarian cancer. In addition, we show targeted silencing of multiple growth-promoting genes (POSTN, FAK, and PLXDC1) along with therapeutic efficacy in the SKOV3ip1, HeyA8, and A2780 models using siRNA incorporated into RGD-CH-NP (siRNA/RGD-CH-NP). Furthermore, we show in vivo tumor vascular targeting using RGD-CH-NP by delivering PLXDC1-targeted siRNA into the alphanubeta3 integrin-positive tumor endothelial cells in the A2780 tumor-bearing mice. This approach resulted in significant inhibition of tumor growth compared with controls. CONCLUSIONS: This study shows that RGD-CH-NP is a novel and highly selective delivery system for siRNA with the potential for broad applications in human disease. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 3910~3922 | - |
dc.relation.isPartOf | CLINICAL CANCER RESEARCH | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Antineoplastic Agents/administration & dosage | - |
dc.subject.MESH | Blotting, Western | - |
dc.subject.MESH | Chitosan/administration & dosage* | - |
dc.subject.MESH | Chitosan/chemistry | - |
dc.subject.MESH | Drug Delivery Systems/methods | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Gene Silencing | - |
dc.subject.MESH | Genetic Therapy/methods* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Mice | - |
dc.subject.MESH | Mice, Nude | - |
dc.subject.MESH | Nanoparticles/administration & dosage* | - |
dc.subject.MESH | Nanoparticles/chemistry | - |
dc.subject.MESH | Neoplasm Proteins/genetics | - |
dc.subject.MESH | Oligopeptides/administration & dosage* | - |
dc.subject.MESH | Oligopeptides/chemistry | - |
dc.subject.MESH | Ovarian Neoplasms/genetics | - |
dc.subject.MESH | Ovarian Neoplasms/therapy* | - |
dc.subject.MESH | RNA, Small Interfering/administration & dosage* | - |
dc.subject.MESH | Receptors, Cell Surface/genetics | - |
dc.subject.MESH | Reverse Transcriptase Polymerase Chain Reaction | - |
dc.subject.MESH | Xenograft Model Antitumor Assays | - |
dc.title | Targeted gene silencing using RGD-labeled chitosan nanoparticles | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Obstetrics & Gynecology (산부인과학) | - |
dc.contributor.googleauthor | Hee Dong Han | - |
dc.contributor.googleauthor | Lingegowda S. Mangala | - |
dc.contributor.googleauthor | Jeong Won Lee | - |
dc.contributor.googleauthor | Mian M.K. Shahzad | - |
dc.contributor.googleauthor | Hye Sun Kim | - |
dc.contributor.googleauthor | Deyu Shen | - |
dc.contributor.googleauthor | Eun Ji Nam | - |
dc.contributor.googleauthor | Edna M. Mora | - |
dc.contributor.googleauthor | Rebecca L. Stone | - |
dc.contributor.googleauthor | Chunhua Lu | - |
dc.contributor.googleauthor | Sun Joo Lee | - |
dc.contributor.googleauthor | Ju Won Roh | - |
dc.contributor.googleauthor | Alpa M. Nick | - |
dc.contributor.googleauthor | Gabriel Lopez-Berestein | - |
dc.contributor.googleauthor | Anil K. Sood | - |
dc.identifier.doi | 10.1158/1078-0432.CCR-10-0005 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01262 | - |
dc.relation.journalcode | J00564 | - |
dc.identifier.pmid | 20538762 | - |
dc.contributor.alternativeName | Nam, Eun Ji | - |
dc.contributor.affiliatedAuthor | Nam, Eun Ji | - |
dc.citation.volume | 16 | - |
dc.citation.number | 15 | - |
dc.citation.startPage | 3910 | - |
dc.citation.endPage | 3922 | - |
dc.identifier.bibliographicCitation | CLINICAL CANCER RESEARCH, Vol.16(15) : 3910-3922, 2010 | - |
dc.identifier.rimsid | 50937 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.